Takeda Pharmaceutical Co. Ltd. has agreed to divest a portfolio of around 110 of non-core, over-the-counter (OTC) and prescription pharmaceutical products it sells in Europe to Orifarm, in a deal worth up to $670m.
The Danish firm will pay around $505m in cash at closing and some $70m in non-contingent cash within four years....
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?